Challenges and risks of using GLP-1 antagonists in treating type 2 diabetes and obesity

• Main Authors: Agnieszka Głuszczyk (Author), Jakub Plizga (Author), Aleksandra Makłowicz (Author), Ewelina Kopczyńska (Author), Angelika Szpulak (Author), Agata Frańczuk (Author), Michalina Grzelka (Author), Julia Głoskowska (Author), Katarzyna Kuleta (Author), Patrycja Karkos (Author)
• Format: Book
• Published: Nicolaus Copernicus University in Toruń, 2024-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Introduction: Ozempic (semaglutide) is a long-acting GLP-1 receptor agonist widely used to treat type II diabetes and obesity. Its mechanism of action includes stimulation of insulin secretion, inhibition of glucagon secretion, and delaying gastric emptying, which leads to lower blood glucose levels...